Abstracts Archive - Page 455 of 2605 - ACR Meeting Abstracts

Abstract Number: 1874 • ACR Convergence 2023
Cartilage Thickness Measures Are More Responsive Than Cartilage Area Loss Measures: A Comparison of Quantitative and Semi-quantitative Cartilage Assessments from the Osteoarthritis Initiative
Aaron Ray¹, Alan Brett², Bright Dube³, Michael Bowes⁴ and Philip Conaghan³, ¹York and Scarborough Teaching Hospitals: NHS Foundation Trust, York, United Kingdom, ²Stryker, Austin, TX, ³University of Leeds, Leeds, United Kingdom, ⁴Imorphics Ltd, Manchester, United Kingdom
Background/Purpose: Cartilage loss in 1-2 year osteoarthritis clinical trials is often small, but a critical outcome measure. The aim of this study was to compare…
Abstract Number: 1935 • ACR Convergence 2023
Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Marion THOMAS¹, Maeva MASSON², Raphaele Seror³, Samuel Bitoun⁴, Henry DUPUY⁵, Lazato ESTIBALIZ⁵, Christophe Richez⁶, Yannick ALLANORE⁷ and Jerome AVOUAC⁸, ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²CHU Toulouse, Toulouse, France, ³University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁴CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, ⁵CHU Bordeaux, Bordeaux, France, ⁶Université de Bordeaux, Bordeaux, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…
Abstract Number: 1943 • ACR Convergence 2023
IgG4-related Disease: 2010-2022 Case Review and Comparative Evaluation of Diagnostic Criteria
Pablo Martínez Calabuig¹, Jorge Juan Fragio¹, Roxana Gonzalez Mazarío², Amalia Rueda Cid³, Mireia Lucía Sanmartín Martínez¹, Laura Salvador Maicas¹, Laura Abenza Barberá¹, María Cristina Sabater Abad¹, Antonio Sierra Rivera¹, Inmaculada Castelló Miralles¹, Juan José Lerma Garrido¹, Clara Molina Almela³, Isabel Balaguer Trull¹ and Cristina Campos Fernández¹, ¹Hospital General Universitario Valencia, Valencia, Spain, ²Hospital de Sagunto, Valencia, Spain, ³Hospital General de Valencia, Valencia, Spain
Background/Purpose: IgG4 immunoglobulin-related disease (IgG4-RD) is a rare, systemic immune-mediated fibro-inflammatory process with an unclear etiology and pathophysiology with the capacity of affecting multiple organs.…
Abstract Number: 1945 • ACR Convergence 2023
Case Series of 6 Patients Exhibiting Myositis as a Rheumatologic Adverse Events Related to Cancer Immunotherapy in Two Spanish Hospitals
Arturo Llobell¹, Inigo Gonzalez-Mazon², carmen secada³, Adrian Martin-Gutierrez³, Almudena García-Castaño³, Enrique Gallardo⁴, Soledad Retamozo⁵, Antonio Gomez-Centeno⁶, Luis Fernandez-Morales⁴, Jordi Gratacos Masmitja⁷ and Ricardo Blanco⁸, ¹Parc Tauli University Hospital, Barcelona, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Parc Taulí University Hospital, Sabadell, Spain, ⁵Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Barcelona, Spain, ⁶Parc Taulí Hospital Universitari, Sabadell, Spain, ⁷University Hospital Parc Taulí, Sabadell, Spain, ⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Myositis is a rare inflammatory complication associated with immune related adverse events (irAE) of immune checkpoints inhibition (ICI) immunotherapy1. It is characterized by musculoskeletal…
Abstract Number: 1947 • ACR Convergence 2023
National Incidence, Prevalence & Mortality in Idiopathic Inflammatory Myopathies & Associated Interstitial Lung Disease in England
Jennifer Hannah¹, Fiona Pearce², Myron Odingo², Megan Rutter², Jeanette Aston³, Jennifer Lai³, Matthew Grainge², Sean Mcphail³, Peter Lanyon², Mary Bythell³, James Galloway⁴ and Patrick Gordon⁵, ¹King's College London, London, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³National Disease Registration Service, Leeds, United Kingdom, ⁴King's College London, London, United Kingdom, ⁵NHS, London, United Kingdom
Background/Purpose: Ethnicity, sex, age & socioeconomic deprivation can all lead to health inequity. Impact of these factors in epidemiology of Idiopathic Inflammatory Myopathies (IIM) has…
Abstract Number: 1939 • ACR Convergence 2023
Sinonasal Sarcoidosis Associated with Chronic Pulmonary Disease, Deficiency Anemias, and Obesity
Emily Kokush, Mary Salim, Eugenio Capitle, Reena Khianey and Evelyne Kalyoussef, Rutgers New Jersey Medical School, Newark, NJ
Background/Purpose: Sarcoidosis is a systemic granulomatous inflammatory disease that can involve multiple organ systems. Rarely, sarcoidosis can involve the upper respiratory tract including the sinonasal…
Abstract Number: 1931 • ACR Convergence 2023
Anti-Ku Antibodies: A Case Series
Raquel Ugena García¹, Cristina Calomarde Gomez¹, Joan Climent² and Lourdes Mateo Soria², ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Anti-Ku antibodies (Abs) were initially described in patients with polymyositis and scleroderma. Subsequently, an association has been demonstrated with other systemic autoimmune diseases (SADs),…
Abstract Number: 1955 • ACR Convergence 2023
Responsiveness and Minimal Important Difference of PROMIS Pain Interference, Fatigue, and Physical Function Forms in Adults with Idiopathic Inflammatory Myopathies
Didem Saygin¹, Dana Direnzo², Joost Raaphorst³, Jin Kyun Park⁴, Ingrid de Groot⁵, Clifton Bingham⁶, Ingrid Lundberg⁷, Malin Regardt⁸, catherine Sarver⁹, Marianne de Visser¹⁰, lara maxwell¹¹, Dorcas Beaton¹², Ju Yeon Kim¹³, Merrilee Needham¹⁴, Helene Alexanderson¹⁵, Lisa Christopher-Stine⁶ and Christopher Mecoli¹⁶, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pennsylvania, Bala Cynwyd, PA, ³Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ⁴Seoul National University Hospital and College of Medicine, Seoul, South Korea, ⁵N/A, Amsterdam, Netherlands, ⁶Johns Hopkins University, Baltimore, MD, ⁷Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, ⁸Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁹N/A, Baltimore, MD, ¹⁰University of Amsterdam, Amsterdam, Netherlands, ¹¹University of Ottawa, Ottawa, ON, Canada, ¹²Institute for Work & Health, Toronto, ON, Canada, ¹³Seoul National University Hospital, Seoul, South Korea, ¹⁴IIID Murdoch University and University of Notre Dame, Perth, Australia, ¹⁵Karolinska Institutet, Stockholm, Sweden, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patient reported outcome measures (PROMs) are critical in assessing clinical outcomes. There is a paucity of PROMs for use in patients with adult idiopathic…
Abstract Number: 1952 • ACR Convergence 2023
Anti-MDA5 Associated Dermatomyositis: Clinical Features and Outcomes in a Predominantly African-American Case Series
David Wang¹, Arezou Khosroshahi² and Prateek Gandiga², ¹Emory University School of Medicine, Atlanta, GA, ²Emory University, Atlanta, GA
Background/Purpose: Individuals with autoantibodies against melanoma differentiation-associated protein 5 (MDA-5) are reported to have a significant risk of developing rapidly progressive and fatal interstitial lung…
Abstract Number: 1950 • ACR Convergence 2023
Thromboembolic Risk Associated with Intravenous Immune Globulin Use in Patients with Idiopathic Inflammatory Myopathy: A Large Database Study
Rohan Mehta¹, Mike Putman² and Didem Saygin³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Intravenous immune globulin (IVIG) recently received regulatory approval for the treatment of dermatomyositis, one of the idiopathic inflammatory myopathies (IIM). The pivotal randomized trial…
Abstract Number: 1937 • ACR Convergence 2023
Efficacy of Different Treatment Approaches for Cardiac Sarcoidosis
Frank Cai¹, Anisha Paulson¹, Amy Wozniak², Emily Gilbert² and Rochella Ostrowski², ¹Loyola University Medical Center, Oak Park, IL, ²Loyola University Medical Center, Maywood, IL
Background/Purpose: There is currently a lack of a consensus standardized guideline for the treatment of cardiac sarcoidosis (CS) because of its rarity, heterogeneity of disease…
Abstract Number: 1941 • ACR Convergence 2023
Identification of VEXAS Syndrome in Mexican Patients with Inflammatory and Hematologic Manifestations
Eduardo Martin-Nares¹, Beatriz E. Sánchez-Hernández², Peter Grayson³, Jose Crispin¹, Daniel Montante-Montes de Oca², Andrea Hinojosa-Azaola¹, Gabriela Hernandez-Molina¹, Elia Apodaca⁴, Emma M. Groarke⁵, Jesús Delgado-de la Mora², Silvia Méndez-Flores⁶, Armando Gamboa-Domínguez², Bhavisha Patel⁷ and Marcela Ferrada⁸, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ⁴Department of Oncology and Hematology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD, ⁶Department of Dermatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁷National Institutes of Health, Beltsville, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: There is limited information on VEXAS syndrome in the Latin-American population. We aimed to identify UBA1 mutations causing VEXAS syndrome in Mexican patients presenting…
Abstract Number: 1878 • ACR Convergence 2023
MRI-determined Intramuscular Fat Changes During Oral Glucocorticoid Treatment: Findings from a Feasibility Study
Thurkka Rajeswaran¹, Emma Harris², hannah Mathieson¹, John Biglands³, Paul Stewart¹, Ai Lyn Tan¹ and Sarah Mackie⁴, ¹University of Leeds, Leeds, United Kingdom, ²The Open University, Milton Keynes, United Kingdom, ³NIHR Leeds Biomedical Research Centre and Medical Physics and Engineering , Leeds Teaching Hospitals NHS Trust Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Oral glucocorticoid therapy has many adverse effects including insulin resistance and myopathy. Long-term glucocorticoid therapy causes a "sarcopenic obesity" phenotype of adiposity with muscle…
Abstract Number: 1879 • ACR Convergence 2023
Artificial Intelligence for the Detection of Sacroiliitis on Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis
Seulkee Lee¹, Uju Jeon², Ji Hyun Lee³, Seonyoung Kang¹, Hyungjin Kim¹, Jaejoon Lee¹, Myung Jin Chung², Jinseok Kim⁴, Eun-Mi Koh⁵ and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Medical AI Research Center, Samsung Medical Center, Seoul, South Korea, ³Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Department of Rheumatology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju-si, Jeju-do, South Korea, La Jolla, CA, South Korea, ⁵Health Insurance Review and Assessment Service, Seoul, South Korea
Background/Purpose: Magnetic resonance imaging (MRI) is important for the early detection of axial spondyloarthritis (axSpA). However, evaluation of sacroiliitis on MRI requires expertise because degenerative…
Abstract Number: 0224 • ACR Convergence 2023
Risk Factors and Outcomes for Repeat COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Case-control Study
Emily Kowalski¹, Xiaosong Wang¹, Naomi Patel², Yumeko Kawano¹, Claire Cook², Kathleen Vanni¹, Grace Qian¹, Katarina Bade³, Shruthi Srivatsan², Zachary Williams², Zachary Wallace⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: As initial COVID-19 infections become nearly ubiquitous and the available prevention and treatment strategies evolve, patients with systemic autoimmune rheumatic diseases (SARDs) may be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].